BACKGROUND: The prognosis is poor for patients who have relapsed-refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first-salvage AML or in studies that were conducted before 2000. Several novel agents and strategies are being tested for potential approval as treatment for patients with relapsed-refractory AML in second salvage. Therefore, it is important to establish the historic results of anti-AML therapies in this setting in the modern era. The objective of the current study was to analyze the results from second salvage therapies in patients with AML since 2000 with regard to response and survival. METHODS: In total, 673 patients who received second salvage therapies for AML since 2000 were analyzed. Their median age was 60 years (range, 18-89 years). Salvage therapy consisted of cytarabine-based regimens in 267 patients, noncytarabine combinations in 37, hypomethylating agent-based regimens in 136, and phase 1 and 2 single agents in 233. RESULTS: Eighty-six of the 673 patients (13%) achieved a complete response (CR) or a CR with low platelet count (CRp). The median duration of CR-CRp was 7.2 months. The median survival was 4.4 months (95% confidence interval, 4.0-4.8 months), and the 1-year survival rate was 16% (95% confidence interval, 14%-19%). Multivariate analysis identified the following as independent adverse factors for achievement of CRCRp: platelets < 50 3 10 9 /L (P <.001), complex karyotype with 3 chromosomal abnormalities (P 5.02), regimens that did not include cytarabine or hypomethylating agents (P 5.014), and no prior CR lasting 12 months with frontline or salvage 1 therapies (P <.001). The independent adverse factors associated with worse survival were age 60 years (P 5.01), platelets < 50 3 10 9 /L (P 5.02), peripheral blasts 20% (P 5.03), albumin 3 g/dL (P 5.04), and complex karyotype (P 5.003). The authors also applied and validated, in the current population, the 2 multivariate-derived prognostic models for CR and survival developed in their previous study of 594 patients who received treatment for second salvage AML from the previous 2 decades. CONCLUSIONS: This large-scale analysis establishes the modern historic results of second salvage therapy in AML and validates the prognostic models associated with outcome. These data could be used to analyze the differential benefits of current or future investigational strategies under evaluation in this setting and for the purpose of potential approval of new agents in the United States and the world. Cancer 2018;124:2534-40. 
INTRODUCTION
Modern anti-acute myelogenous leukemia (anti-AML) intensive chemotherapy regimens containing anthracyclines and cytarabine result in complete responses (CRs) in 60% to 70% of patients and in cure rates for 20% to 50%. The prognosis of patients with AML depends on several characteristics, including patient age, performance status, organ functions, and comorbid conditions, as well as important leukemia characteristics, including cytogenetic and molecular findings. [1] [2] [3] [4] Patients with refractory-relapsed AML have a poor prognosis. Most of the AML salvage studies have detailed the results in primary refractory AML or AML in first relapse (ie, results and prognosis with first salvage therapy). [5] [6] [7] [8] In first salvage AML, the median survival duration ranges from 3.3 to 7.5 months and depends primarily on 3 factors: patient age, achievement of CR and duration of first CR, and leukemia karyotype. [5] [6] [7] [8] [9] [10] In patients with cancer (eg, multiple myeloma, lymphoma, and lung, gastrointestinal, ovarian, or breast cancer), defining outcomes in second or later salvage strategies resulted in treatment-specific options and the approval of novel therapies by the US Food and Drug Administration (FDA) for these particular salvage situations. In a previous study, we evaluated the outcome of patients with AML after second salvage therapy and identified prognostic factors associated with response and survival. We noted that the prognosis of patients improved significantly since 1991, probably as a result of better supportive care. 11 A similar observation was noted for patients with AML in first salvage since 2008 compared with earlier periods. 10 Defining the outcome of patients with AML who receive second salvage therapy in the modern era would help advise patients about their treatment options; design more optimized regimens; define the precise historic outcome of second salvage therapies against which current and future salvage regimens could be compared; and explore opportunities for potential approval, by the FDA in the United States or by other regulatory agencies in the world, of new agents under investigation in AML for the narrow indication of second salvage in AML. This is particularly important because of the introduction of nonintensive regimens (eg, epigenetic therapy) as frontline and first salvage therapies in patients who are not candidates for intensive chemotherapy.
MATERIALS AND METHODS

Study Group
Adults with a diagnosis of AML who were referred to or treated at our institution using second salvage strategies from 2000 to 2016 were included in this analysis. First salvage AML therapy was defined as first therapy for either primary refractory AML or AML in first relapse. Second salvage AML therapy was the therapy that followed it immediately, regardless of the first salvage response. Informed consent for second salvage therapy was obtained according to institutional guidelines. The study was approved under an Institutional Review Board-approved protocol.
Therapy
Second salvage regimens were grouped into the following main categories: 1) cytarabine-containing regimens; 2) non-cytarabine combinations; 3) regimens containing hypomethylating agents, such as azacitidine, decitabine, or guadecitabine; and 4) single-agent phase 1/2 studies. Patients with core-binding factor (CBF) AML and those who underwent allogeneic stem cell transplantation (SCT) for active AML were analyzed separately.
Statistical Considerations
Response criteria were as previously defined. A CR required normalization of the bone marrow, with 5% bone marrow blasts, and of peripheral counts, with granulocytes 10
9
/L and platelets 100 3 10 9 /L. A CR without recovery of platelets to 100 3 10 9 /L without transfusions was called a CRp. A partial response (PR) was the same as a CR but with persistent 6% to 25% bone marrow blasts. 12 A bone marrow CR referred to the achievement of 5% blasts in the bone marrow without recovery of platelets or neutrophils; sometimes, this is referred to in the literature a CR-incomplete (CRi) or bone marrow leukemia-free infiltrate. Survival was calculated from the start of second salvage therapy. Survival probabilities were calculated using the Kaplan-Meier method. Differences in CR rates and survival were compared according to pretreatment characteristics and therapies using subgroups of clinically relevant categories. Differences in CR rates were compared using the chisquare test. The log-rank test was used to compare survival. 13 In multivariate analyses to define independent prognostic factors associated with response (CR 1 CRp) and with survival, we used standard statistical methods, including logistic regression models and Cox proportional-hazards models. 11, 14, 16 Two multivariate-derived prognostic models, 1 for achieving a CR and the other for survival, were previously developed in 594 patients with AML who received second salvage therapy. 11 These models were developed using standard statistical methods, as previously detailed. 11, [14] [15] [16] The models, which were tested for their capacity to predict for CR and survival in the current population, are summarized in Supporting Table 1.   11 Two groups of patients were analyzed separately and were not part of the multivariate analysis because of their vastly different outcomes in the current analysis and in previous studies. These included 36 patients who had CBF AML and 69 who underwent allogeneic SCT as their Original Article second salvage therapy during an active disease stage. The details of their outcomes are outlined separately (see Fig. 1 ).
RESULTS
Response and Outcome
Characteristics of the 673 patients who received second salvage therapy at our institution are listed in Table 1 . Their median age was 60 years (range, 18-89 years), 343 (51%) were aged 60 years, and 312 (46%) were women. Overall, 61 patients (9%) achieved a CR with second salvage therapy, and 25 patients had a CRp (4%), for an overall CR 1 CRp response rate of 13%. In addition, 56 patients achieved bone marrow CR, and 6 had PR ( Table 2 ). The median duration of CR-CRp was 7.2 months. The 6-month survival rate was 39%, and the 1-year survival rate was 16% (Fig. 1) . Survival by response is illustrated in Figure 2A and by therapy in Figure 2B .
Multivariate Analyses for CR-CRp and Survival
The prognostic factors associated with significant differences in CR-CRp rates and in survival were determined in univariate analyses and are provided in Supporting Table  2 . In multivariate analysis, the independent adverse factors associated with worse response rates were: platelets < 50 3 10 9 /L (P < .001), complex karyotype with 3 chromosomal abnormalities (P 5 .02), noncytarabine or nonhypomethylating regimens (P 5 .01), and no prior CR 12 months with frontline or salvage 1 therapies (P < .001). The independent adverse factors associated with worse survival were: age 60 years (P 5 .01), platelets < 50 3 10 9 /L (P 5 .02), peripheral blasts 20% (P 5 .03), albumin 3 g/dL (P 5 .04), and complex karyotype (P 5 .003) ( Table 3) . Because the identified factors were similar or were strongly interrelated with the identified adverse factors in our previous analysis, we elected to validate the previously identified prognostic models in the current population rather than proposing new prognostic models, which would need to be validated in independent AML salvage 2 study groups.
Testing the Older CR and Survival Models in the Current Population
The previous multivariate analyses had identified independent adverse prognostic factors for CR and survival (Supporting Table 1 ). 11 We analyzed the outcomes of the 673 patients according to the number of adverse factors (excluding the adverse factor of "therapy before 1991," because it was not applicable to the current study group). Table 4 indicates that the patients could be grouped into risk subcategories with notable differences in response and survival outcomes.
Outcome of Patients with CBF AML
In total, 36 patients with CBF AML received salvage 2 therapy. Twenty-eight patients (78%) had a first remission duration longer than 12 months. Twenty patients received cytarabine-based therapies, 4 underwent allogeneic SCT, and 12 received other agents. The overall CR 1 CRp rate was 33% ( Table 2 ). The 1-year survival rate was 28%, and the 2-year survival rate 14% (Fig. 1) .
Outcome of Patients Who Underwent Allogeneic SCT
In total, 69 patients underwent allogeneic SCT with active disease as a salvage 2 strategy. These excluded the patients who had CBF AML discussed above. Among the 69 patients, the CR rate was 51%, and the overall response rate was 88% (Table 2) ; the 1-year survival rate was 43%, and the 2-year survival rate was 29% (Fig. 1) . These results are better than those reported from a previous experience in 74 patients (1-year survival, 16%), 11 suggesting either better patient selection or an improvement in the results of modern allogeneic SCT therapy.
Because a strong selection bias may apply to the decision to undergo allogeneic SCT (patient age, proliferative disease, percentage blasts, performance status, comorbid conditions, donor availability), we analyzed the characteristics of the 69 patients who underwent allogeneic SCT versus the remaining patients (Table 5) . Those who were accepted for allogeneic SCT were significantly younger and had lower incidences of thrombocytopenia, elevated percentages of blasts in the blood and bone marrow, lactic dehydrogenase elevations, and high white blood cell counts.
The 5-year survival rate was 20% among patients who had <20% bone marrow blasts versus <10% among those who had 20% bone marrow blasts. Similarly, the 5-year survival rate was 22% among patients who had <20% peripheral blasts versus 0% among those who had 20% peripheral blasts (Fig. 3) .
Outcome of Patients who Underwent Allogeneic SCT Postsalvage 2 Therapy Either in Third Remission or With Active Disease
In total, 53 patients underwent allogeneic SCT after receiving AML salvage 2 therapy either in third CR or CRp (n 5 35 of 86 patients in CR-CRp accessing SCT) or in PR or bone marrow CR (n 5 18 of 62 patients in PR-bone marrow CR accessing SCT). Among these 53 patients, the 2-year survival rate from SCT was 29% (27% for those in CR-CRp; 36% for those in PR-bone marrow CR). In total, 76 patients, either in some form of response (n 5 10) or with active disease (n 5 66; 48 of the 66 patients [73%] achieved CR-CRp after SCT), underwent allogeneic SCT in salvage 3 and beyond. Their 2-year survival rate post-SCT was 22%.
Outcomes Based on Durations of First and Second CRs
In common practice, the durations of first and second CRs are used as simple prognostic determinants. 11 In the current study, the simplified model based on the durations of first and second CRs was not predictive of salvage 2 CR rates or survival (Table 6 ). Low-intensity and epigenetic therapies have gained more acceptance recently as potential therapies for patients with AML, in contrast to historic data in which almost all patients received cytarabine-based or other intensive therapies as frontline or salvage therapies. This may explain why the simplified model was not predictive in recent times (less intensive chemotherapy, hence less capacity to achieve true CRs with frontline-first salvage therapies).
DISCUSSION
The objective of this large-scale analysis of 673 patients with AML who received second salvage therapy was to define the baseline outcome expectations with second salvage therapy in the modern era. This is a therapeutic situation in which no standard of care has been established and against which multiple novel and exciting therapies could be evaluated for potential FDA approval, ( Among the 673 patients who received treatment, the CR rate was 9%, and the CR 1 CRp rate was 13%. The median survival was 4.4 months, the 6-month survival rate was 39%, and the 1-year survival rate was 16%. The 6-month survival rate of 39% was similar to what was reported for such patients treated since 1991 (6-month survival rate, 38%), 11 attesting to the stability of the historic results since then, regardless of therapies used until now.
When we applied the 2 previous multivariatederived prognostic models for CR and survival to the present population, they revealed discriminant differences in outcomes for both CR and survival with each of the 2 models. The simplified prognostic model based solely on durations of first and second CRs did not predict as well for CR rates and for survival. This may be because of the recent changes in frontline and first salvage therapies offered to patients.
Most patients with active AML are rejected for salvage SCT options based on the historically very poor results and low salvage cure rates (less than 5%-10%). A subset analysis of the 69 patients who underwent allogeneic SCT as second salvage therapy indicated that a lower peripheral blast percentage (<20%) was associated with a reasonable 5-year survival rate of 20% (vs 0% for higher blast counts) (Figs. 1 and 3) , a factor to be considered in the future selection of patients for allogeneic SCT. In addition, patients who underwent allogeneic SCT beyond salvage 2 still had reasonable 2-year survival rates, suggesting that allogeneic SCT should remain a treatment consideration at any time during the disease course for patients with relapsed-refractory AML.
In summary, this analysis established the baseline expectations of outcomes in a large population of patients with AML who received second salvage therapies. It also validated the 2 previously proposed risk models for CR and survival. Abbreviations: CR, complete response; CRD1, duration of first complete response; CRD2, duration of second complete response; CRp, complete response with low platelet count.
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